Publications and  research impact

Academic publications

1. 1. Parvanova, I., Mungiu-Pippidi, A. (2026) "Does Corruption Increase Inequality? Evidence from a European Union Fact-Based Assessment" . Regulation and Governance  https://doi.org/10.1111/rego.70196

   2. Allin, S., Kyriopoulos, I. and Parvanova, I. (2026) 'Informal payments in health care', in Cylus, J., Forman, R., Shuftan, N., Mossialos, E. and Smith, P.C. (eds.) Paying for Health: Learning from International Experience. Cambridge University Press, pp. 360–404.

   3. Gentilini, A., Parvanova, I., Ghazi, S., Scarfone, K. M., & Kohler, J. (2026). Patient organizations involvement in healthcare: a rapid review and conceptual framework. Globalization and Health, 22(1), 43.,  https://doi.org/10.1186/s12992-026-01205-z  

   4. Parvanova, I. and Lagarde, M. (2025), Framing of sensitive topics in surveys measuring corruption in healthcare. Social Science and Medicine, https://doi.org/10.1016/j.socscimed.2024.117521

   5. Gentilini, A. and Parvanova, I. (2024), Managing experts’ conflicts of interest in the EU Joint Clinical Assessment. BMJ Open, https://bmjopen.bmj.com/content/14/11/e091777 

   6. Parvanova, I. (2024). Institutional characteristics and social norms as drivers of petty corruption in healthcare - a multilevel latent class analysis. Governance,  https://doi.org/10.1111/gove.12868 

   7. Osipenko, L., Potey, P., Perez, B., Angelov, F., Parvanova, I., Ul-Hasan, S. and Mossialos, E. (2024), The Origin of First-in-Class Drugs: Innovation Versus Clinical Benefit, Clinical Pharmacology & Therapeutics, https://doi.org/10.1002/cpt.3110 

   8. Gentilini, A. and Parvanova, I. (2023) Industry funding of patient organisations in the United Kingdom: a retrospective study of commercial determinants, funding concentration and disease prevalence. BMJ Open, http://dx.doi.org/10.1136/bmjopen-2022-071138

Policy publications

1. 1. Parvanova, I. (2026), Sustainability of Anti-Corruption Reforms and Interventions. Transparency International Helpdesk Answer, https://knowledgehub.transparency.org/helpdesk/sustainability-of-anti-corruption-interventions-and-reforms

   2. Parvanova, I. (2025), The Use of Big Data by Anti-Corruption Authorities. U4 Anti-Corruption Resource Center and Transparency International Helpdesk Answer : 34, https://knowledgehub.transparency.org/helpdesk/the-use-of-big-data-by-anti-corruption-authorities 

   3. Mungiu-Pippidi, A. and Parvanova, I. (2025), Understanding Integrity: The causes and trends of corruption risk in Europe 41. European Research Center for Anti-Corruption and State-Building Working Paper 66, https://shorturl.at/cFpik (Prepared as a report to the European Commission)

   4. Parvanova, I., Gentilini, A., Cushing, J., & Naci, H. (2023). Safeguarding NICE from patient groups’ conflicts of interest. BMJ, 381, https://doi.org/10.1136/bmj.p1243 

Under review and work in progress

1. 1. Favoritism and corrupt reciprocity - a lab-in-the-field experiment (with Prof Mylene Lagarde (LSE))

   2. Evidence on the implementation and effectiveness of administrative anti-corruption interventions and their lessons for the healthcare system - a systematic review of evaluations (with Prof Dina Balabanova (LSHTM))

   3. Corruption in the supply chain of generic antibiotics - assessing the drivers of counterfeit and falsified drugs (with Transparency International)

   4. Corruption and citizenship by investment (with Prof Alina Mungiu-Pippidi (LUISS))

   5. A retrospective study of conflicts of interest in the French pharmaceutical industry  (with Arianna Gentilini (LSE) and Prof Jillian Kohler (Univeristy of Toronto))

   6. Political Finance Transparency in Europe (with Prof Alina Mungiu-Pippidi (LUISS) and Nicolas Soto (LUISS)